Skip to content

Doppler Evaluation for Congestive Acute Kidney Injury in Critical Illness

The Impact of VeXUS-guided Fluid Management in ICU Populations on Renal Function

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07291778
Acronym
DECONGEST-AKI
Enrollment
100
Registered
2025-12-18
Start date
2026-12-01
Completion date
2028-12-01
Last updated
2026-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, VExUS

Keywords

VExUS, Fluid Management, Acute Kidney Injury, ICU

Brief summary

This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB.

Detailed description

This study will evaluate the use of the Venous Excess Ultrasound (VExUS) score to guide fluid management in critically ill ICU patients through a prospective, multi-aim design combining observational and randomized components. The study will be conducted in the medical intensive care unit (MICU), multidisciplinary critical care unit (MCCU), and cardiac care unit (CCU) at UAB. Informed Arm: The treating team receives the patient's VExUS results and management recommendations. Not-Informed Arm: The treating team remains blinded to all VExUS findings and receives no feedback or recommendations. Each enrolled patient will undergo two VExUS ultrasound assessments: Timepoint 1 (enrollment): Two scans are performed by separate operators to assess waveform reliability and inter-user reproducibility. Timepoint 2 (48-72 hours after enrollment): A single scan is performed along with concurrent collection of serum creatinine, intake/output (I&O) balance, and renal replacement therapy (RRT) status. Each VExUS exam includes Doppler evaluation of the inferior vena cava, hepatic vein, portal vein, renal cortical artery, and renal cortical vein. Scans are saved to secure UAB SharePoint storage labeled with an auto-incrementing study ID. Blinding Procedures To maintain study integrity and minimize bias, multiple layers of blinding will be employed: Scanner Blinding: Sonographers performing the VExUS scans are blinded to the patient's randomization status and to all prior scan results. They collect and upload de-identified images labeled only by study ID. Interpreter Blinding: The attending physician interpreting the scans (the "overreader") is blinded to randomization status during the image interpretation phase. The overreader reviews both scans for quality and assigns a VExUS score (0-3) before randomization status is revealed. Recruiter/Coordinator Role: The research coordinator (unblinded) maintains the randomization list and is responsible for communicating the overread results to the treating team only for patients in the informed arm. Primary Team Blinding: For patients in the not-informed arm, the primary clinical team will not receive any VExUS scores or recommendations, and no study-related documentation will be visible in the electronic health record (EHR). Statistical Blinding: Data analysts will remain blinded to treatment arm allocation until after all primary outcomes are recorded. Communication and Clinical Guidance For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score: VExUS = 0: Recommend a net positive fluid balance. VExUS = 1: Recommend a net neutral fluid balance. VExUS \>= 2: Recommend a net negative fluid balance. These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team. Data Management and Analysis Two linked data lists will be maintained: Master List (PHI-protected): Contains patient identifiers and MRNs, stored on a secure UAB server. Patient Data List (de-identified): Contains study ID, randomization arm, scan quality, interpreter scores, creatinine values, I&O data, RRT status, ICU-free days, hospital-free days, and mortality. All ultrasound procedures are noninvasive and adhere to ACEP emergency ultrasound standards. Protected health information will remain secured on institutional servers, and only de-identified data will be used for analysis.

Interventions

OTHERFluid Management

For patients in the informed arm, the overreader will generate standardized recommendations based on the VExUS score: VExUS = 0: Recommend a net positive fluid balance. VExUS = 1: Recommend a net neutral fluid balance. VExUS \>= 2: Recommend a net negative fluid balance. These recommendations will be communicated to the treating team via a structured process: documentation in the EHR under the POCUS note and verbal handoff to the resident, fellow, and attending on the primary team.

OTHERNo intervention

Primary team will not be informed about the patient's VExUS score and will not be given recommendations for fluid management

Sponsors

University of Alabama at Birmingham
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Masking description

To maintain study integrity and minimize bias, multiple layers of blinding will be employed: Scanner Blinding: Sonographers performing the VExUS scans are blinded to the patient's randomization status and to all prior scan results. They collect and upload de-identified images labeled only by study ID. Interpreter Blinding: The attending physician interpreting the scans (the "overreader") is blinded to randomization status during the image interpretation phase. The overreader reviews both scans for quality and assigns a VExUS score (0-3) before randomization status is revealed. Recruiter/Coordinator Role: The research coordinator (unblinded) maintains the randomization list and is responsible for communicating the overread results to the treating team only for patients in the informed arm. Primary Team Blinding: For patients in the not-informed arm, the primary clinical team will not receive any VExUS scores or recommendations, and no study-related documentation will be visible in

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults (≥18 years old) * Admitted to the MICU, MCCU, or CCU within 24 hours of admission * Acute kidney injury (AKI) (based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria) * Adequate acoustic windows for a complete VExUS scan

Exclusion criteria

* \< 18 years old * pregnant women * End-stage renal disease (ESRD) or prior renal transplant * Acute tubular necrosis (ATN) defined by urinalysis (≥2+ protein, ≥2+ blood, ≥1 muddy brown cast, ≥1 RBC cast, or ≥1 dysmorphic RBC)' * Prior Whipple procedures * currently incarcerated

Design outcomes

Primary

MeasureTime frameDescription
In-hospital Mortalityup to 30 daysIn-hospital mortality: Death from any cause before hospital discharge, within the 30-day window.
Renal Replacement Therapyup to 30 daysNew receipt of Renal Replacement Therapy (RRT): Receiving dialysis or another form of RRT for the first time.
Persistent Renal Dysfunctionup to 30 daysPersistent renal dysfunction: The final serum creatinine value before hospital discharge (within 30 days) is 200% (twice) or more of the patient's baseline creatinine value.

Countries

United States

Contacts

CONTACTTimothy I Kennell, MD, PhD
tkennell@uabmc.edu2059965864
CONTACTSteve Fox, MD
swfox@uabmc.edu2059965864

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 17, 2026